in october 2014, chimerix reported it had been given approval by the fda to start phase 2 trials in patients infected with ebolaviruses for brincidofovir's safety, tolerability, and efficacy. a trial commenced during january 2015 in liberia, but was subsequently discontinued. because of a lack of suitable subjects in liberia, oxford university and médecins sans frontières planned to extend the trial to sierra leone, where there were still ebola cases; but on the 30th of january 2015, the manufacturer decided to withdraw support for the trial and end discussion of future trials.